Head and neck cancer (HNC) is defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate evidence obtained since 2013 publication, Spanish Society of Medical Oncology (SEOM) presents an update of HNC diagnosis and treatment guideline. The eighth edition of TNM classification, published in January 2017, introduces important changes for p16-positive oropharyngeal tumours, for lip and oral cavity cancer and for N3 category. In addition, there are new data about induction chemotherapy and the role of immunotherapy in HNC.
26 December 2019 in Journal of Translational Medicine
Background: Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognostic factor is controversial. This study investigates whether tumoral expression of PD-L1 is a prognostic marker in patients with recurrent and/or metastatic (R/M) HNSCC treated with standard chemotherapy. Methods: This retrospective, multicenter, noninterventional study assessed PD-L1 expression on archival R/M HNSCC tissue samples using the VENTANA PD-L1 (SP263) Assay. PD-L1 high was defined as PD-L1 staining of ≥ 25% TC, with exploratory scoring at TC ≥ 10% and TC ≥ 50%. The primary objective of this study was to estimate the prognostic value of PD-L1 status in terms of overall survival (OS) in patients with R/M HNSCC. Results: 412 patients (median age, 62.0 years; 79.9% male; 88.2% Caucasian) were included from 19 sites in seven countries. 132 patients (32.0%) had TC ≥ 25% PD-L1 expression; 199 patients (48.3%) and 85 patients (20.6%) had TC ≥ 10% and ≥ 50%, respectively. OS did not differ significantly across PD-L1 expression (at TC ≥ 25% cutoff median OS: 8.2 months vs TC < 25%, 10.1 months, P = 0.55) or the ≥ 10% and ≥ 50% cutoffs (at TC ≥ 10%, median OS: 9.6 months vs TC < 10%, 9.4 months, P = 0.32, and at TC ≥ 50%, median OS 7.9 vs TC < 50%, 10.0 months, P = 0.39, respectively). Conclusions: PD-L1 expression, assessed using the VENTANA PD-L1 (SP263) Assay, was not prognostic of OS in patients with R/M HNSCC treated with standard of care chemotherapies. Trial registration ClinicalTrials.gov, NCT02543476. Registered September 4, 2015.
Background/Objectives: The incidence of thyroid cancer (TC) has increased worldwide over recent decades, particularly for well-differentiated histological subtypes, a trend largely attributed to overdiagnosis. Given potential geographical differences, this study analyzed TC incidence and temporal trends in the province of Girona, Spain, between 2002 and 2021. Methods: We conducted a cross-sectional study using data from the Girona Cancer Registry. Crude incidence rates (CRs), age-standardized incidence rates using the 2013 European (ASRe) and the 1960 World (ASRw) standard populations were calculated per 100,000 person-years. Temporal trends were assessed via the annual percentage change (APC) using generalized linear models. Results: A total of 998 incident TC cases were identified. Most patients were women (78.0%), with a median age at diagnosis of 48 years. Papillary TC was the predominant histological subtype (81.7%), and 70.6% of cases were diagnosed at Stage I. The overall ASRe was 6.8 and ASRw was 5.5, with incidence rates 3–4 times higher in women than in men. Overall, TC incidence increased significantly (APC: 2.7%), driven by increases in the 35–44 and ≥55 age groups, papillary histology, and early-stage disease (Stages I–II). Conclusions: The rise in TC incidence in Girona over the last two decades has been largely driven by Stage I papillary tumors, in both sexes, supporting a potentially substantial contribution of overdiagnosis. However, the concurrent increase in Stage II disease warrants continued surveillance, as it may reflect additional risk factors.